The information was submitted for publication 2018-07-06 at 08.20
On 17 July 2018, at 08:20 publish CellaVision AB (publ) interim report for the second quarter of 2018. The report will be available on the www.cellavision.se
In this connection, invited analysts, investors and media to a audiosänd conference call the same day at 11:00, where president and CEO, Miletic Rihter, will present and comment the report.
The presentation will be conducted in English via a telephone conference or audiosändning on: https://tv.streamfabriken.com/cellavision-q2-2018
Phone number to the conference:
No registration is required. Please call in to the conference 5-10 minutes before the scheduled start time in order to facilitate the start at the appointed time.
CellaVision is an innovative, global medical device company that develops and sells leading systems for routine analysis of blood and other body fluids in health care. The analyses often constitute important basis for the timely and accurate sjukdomsdiagnoser, for example in infections and serious cancers. CellaVisions products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. Expertise is in image analysis, artificial intelligence and automated microscopy. Sales through global partners with support from the parent company in Lund, as well as marknadssupportorganisationer in the united states, Canada, Brazil, China, Japan, south Korea, Australia, Sweden, the United arab Emirates, France, Germany, the Uk, Mexico and India. 2017 net sales 309 Million. The share is listed on Nasdaq Stockholm, Mid Cap. Read more on www.cellavision.se
Invitation telco Q2 comment
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire